Latest News From Pharmachem
-
Irish manufactoring sector growth accelerates in July
04 August, 2015
Irish manufacturing sector growth rebounded from a 16-month low in July as the weak euro boosted exports, a survey showed on Tuesday. The Investec Manufacturing Purchasing Managers’ Index rose to 56.7 in July from 54.6 in June.
-
Dublin based Shire bids $30 billion for Baxter spin-off Baxalta
06 August, 2015
Drugmaker Shire is seeking to buy Baxalta, a company spun-off by Baxter International, for $30 billion (€27.35 billion) to forge the leading global specialist in rare diseases.
-
Revenue at Dublin based Jazz Pharmaceuticals increases by 15% in second quarter
07 August, 2015
Dublin-based Jazz Pharmaceuticals said revenues rose 15 per cent in the second quarter of the year as sales of its Xyrem product increased. The company reaffirmed financial guidance for 2015, which puts revenue in the projected range of $1.31 billion to $1.37 billion
-
Dublin based Mallinckrodt buys immunotherapy drug maker Therakos for $1.33bn
11 August, 2015
Dublin-based drugmaker Mallinckrodt said Monday it would buy immunotherapy company Therakos in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings.
-
Increase of 33% in professional job opportunities
13 August, 2015
There was a 33% increase in the number of professional job opportunities (12,887) when compared with the same month last year (9,699) according to the July 2015 Morgan McKinley Irish Employment Monitor which has been released today.
-
Goodbody Stockbrokers predict that Ireland will be the fastest growing economy in the EU in 2015
14 August, 2015
Goodbody Stockbrokers have today upgraded their economic growth forecasts, and now expect GDP growth of 5.5% in 2015 (previously 4.3%), with 4% expected for both 2016 and 2017.
-
Novartis buys remaining rights to GSK multiple sclerosis compound Ofatumumab
24 August, 2015
Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.
-
Science education programmes accompany new Amgen facility
25 August, 2015
Biotechnology company Amgen, which yesterday unveiled its €260m facility in Dún Laoghaire, has launched two science education courses aimed at reaching more than 53,000 students and hundreds of teachers.
-
Irish medical firm Mainstay receives third US patent
27 August, 2015
Irish medical devices firm Mainstay Medical, which agreed a debt facility of up to $15 million (€13.1 million) earlier this week, has been awarded an additional US patent as it continues with moves to bring a new product to market.
-
Bristol-Myers buys rights to fibrosis drug from private drug maker Promedior
31 August, 2015
Drugmaker Bristol-Myers Squibb said it would buy the worldwide rights to a mid-stage fibrosis drug from privately held Promedior for up to $1.25 billion.